Tender Details
Particulars | Details |
---|---|
Title |
(Ph No.: 49100) Human Growth Hormone Injection Should Have Following Specification: 1. Should Contain Somatotropin Recombinant Dna Origin. 2. Should Be Prefilled, Pre Loaded, Flex Pro Pen With No Need Of External Reconstitution. 3. Minimum 15 N S Of 36 G Disposable Needles For Subcutaneous Use, Should Be Supplied With Each Pen. 4. Growth Charts For Follow Up Of The Patients Who Are On Therapy Should Be Provided. 5. Should Demonstrate The Product And Ease Of Administration. 6. Should Ensur
|
Description |
For Complete Deion And Other Details, Please Refer To Tender
|
Organisation | Ministry of Railways | Central Govt. Ministry/Department |
Tender Id | 76019191 |
Reference Number |
BZAMS2425018D |
Tender Fee | 0 |
EMD | 0 |
Tender Value | |
Place | Secunderabad |
Link | https://www.ireps.gov.in/ireps/supply/pdfdocs/072024/76019191/viewNitPdf_4627446.pdf |
Start Date | July 02, 2024 21:06 |
End Date |
09/07/2024 ( Expired 304 days ago ) Search Similar tenders? |
Join for More Relevant Opportunities |
Similar Tenders
(ph no.: 49100) human growth hormone injection should have following specification: 1. should contain somatotropin recombinant dna origin. 2. should be prefilled, pre-loaded, flex pro pen with no need of external reconstitution. 3. minimum 15 n s of 36g disposable needles for subcutaneous use, should be supplied with each pen. 4. growth charts for follow up of the patients who are on therapy should be provided. 5. should demonstrate the product and ease of administration. 6. should ensur
For complete deion and other details, please refer to tender
Read more(ph no.: 49100) human growth hormone injection should have following specification: 1. should contain somatotropin recombinant dna origin. 2. should be prefilled, pre-loaded, flex pro pen with no need of external reconstitution. 3. minimum 15 n s of 36g disposable needles for subcutaneous use, should be supplied with each pen. 4. growth charts for follow up of the patients who are on therapy should be provided. 5. should demonstrate the product and ease of administration. 6. should ensur
For complete deion and other details, please refer to tender
Read more(ph no.: 49100) human growth hormone injection should have following specification: 1. should contain somatotropin recombinant dna origin. 2. should be prefilled, pre-loaded, flex pro pen with no need of external reconstitution. 3. minimum 15 n s of 36g disposable needles for subcutaneous use, should be supplied with each pen. 4. growth charts for follow up of the patients who are on therapy should be provided. 5. should demonstrate the product and ease of administration. 6. should ensur
For complete deion and other details, please refer to tender
Read more(ph no.: 49100) human growth hormone injection should have following specification: 1. should contain somatotropin recombinant dna origin. 2. should be prefilled, pre-loaded, flex pro pen with no need of external reconstitution. 3. minimum 15 n s of 36g disposable needles for subcutaneous use, should be supplied with each pen. 4. growth charts for follow up of the patients who are on therapy should be provided. 5. should demonstrate the product and ease of administration. 6. should ensur
For complete deion and other details, please refer to tender
Read more(ph no.: 49100) human growth hormone injection should have following specification: 1. should contain somatotropin recombinant dna origin. 2. should be prefilled, pre-loaded, flex pro pen with no need of external reconstitution. 3. minimum 15 n s of 36g disposable needles for subcutaneous use, should be supplied with each pen. 4. growth charts for follow up of the patients who are on therapy should be provided. 5. should demonstrate the product and ease of administration. 6. should ensur
For complete deion and other details, please refer to tender
Read more(ph no.: 49100) human growth hormone injection should have following specification: 1. should contain somatotropin recombinant dna origin. 2. should be prefilled, pre-loaded, flex pro pen with no need of external reconstitution. 3. minimum 15 n s of 36g disposable needles for subcutaneous use, should be supplied with each pen. 4. growth charts for follow up of the patients who are on therapy should be provided. 5. should demonstrate the product and ease of administration. 6. should ensu
For complete deion and other details, please refer to tender
Read more
Click
Here to Download Dockets
of your Industry type
of your Industry type